Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy

Epilepsia

Volumn 37, Issue 8, 1996, Pages 763-768

  Tassinari, C A ^a,h   Michelucci, R ^a   Chauvel, P ^b,c   Chodkiewicz, J ^b,c   Shorvon, S ^d   Henriksen, O ^e   Dam, M ^f   Reife, R ^g   Pledger, G ^g   Karim, R ^g  

^a BELLARIA HOSPITAL   (Italy)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d National Hospital   (United Kingdom)

^e National Center for Epilepsy   (Norway)

^f HVIDOVRE HOSPITAL   (Denmark)

^g R W JOHNSON PHARMACEUTICAL RES I   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiepileptic drug; Partial epilepsy; Secondarily generalized epilepsy; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THOUGHT DISORDER; VERTIGO;

EID: 9444251680     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00649.x     Document Type: Article

References (19)

1. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
2. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans [Abstract]. Epilepsia 1988;29:662.
3. Bialer M. Comparative pharmacokinetics of the newer anti-epileptic drugs. Clin Pharmacokinet 1993;24:441-52.
4. Doose DR, Scott VV, Margul BL, Marriott TB, Nayak RK. Multiple-dose pharmacokinetics of topiramate in healthy male subjects [Abstract]. Epilepsia 1988;29:662.
5. Sussman NM, Heydorn WE. New and investigational antiepilepsy drugs. Exp Opin Invest Drugs 1994;3:355-68.
6. Doose DR, Gisclon LG, Stellar SM, Riffits JM, Hills JF. The effect of food on the bioavailability of topiramate from 100-and 400-mg tablets in healthy male subjects [Abstract]. Epilepsia 1992;33(suppl 3):105.
7. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1981;35:124-33.
8. Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1990.
9. Lehmann EL. Nonparametrics: statistical methods based on ranks, San Francisco: Holden Day, 1975.
10. Ben-Menachem E, Henriksen O, Dam M, Schmidt D. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;36:539-43.
11. Martinez-Lage J, Ben-Menachem E, Shorvon S, Weber M. Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy [Abtract]. Epilepsia 1995;36(suppl 3):S149-50.
12. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
13. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg daily dosages. Neurology 1996;46:1678-83.
14. Wilensky AJ, Ojemann LM, Chmelir T, Margul BL, Doose DR. Topiramate pharmacokinetics in epileptic patients receiving carbamazepine [Abstract]. Epilepsia 1989;30:645.
15. Floren KL, Graves NM, Leppik IE, Remmel RP, Margul BL, Doose DR. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate [Abstract]. Epilepsia 1989;30:646.
16. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and topiramate (Topamax®) in epileptic patients on monotherapy, and during combination therapy [Abstract]. Epilepsia 1994;35(suppl 8):54.
17. Levy RH, Bishop F, Stevens AJ, et al. Explanation and prediction of drug interactions with topiramate using a CYP 450 inhibition spectrum [Abstract]. Epilepsia 1995;36(suppl 4):47.
18. Sussman NM, Heydorn WE. New and investigational antiepilepsy drugs. Exp Opin Invest Drugs 1994;3:355-68.
19. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate [Abstract]. Epilepsia 1995;36 (suppl 3):S153.